Nxstage Medical, Inc. (NXTM)’s SVP and General Counsel Winifred Swan Sold 3,500 Shares of the Company; Profile of 12 Analysts Covering Suncor Energy Inc. (SU)

Calculated with average price per share of $24.9, Winifred Swan, the Nxstage Medical Inc’s SVP and General Counsel made a sale of 3,500 shares of Nxstage Medical Inc worth approx. $87,080 U.S. Dollars. In the last 30 days, she also sold 3,500 shares worth approximately $88,725 USD. She owns 0.02% of the -company’s market cap or 10,270 shares.

Among 15 analysts covering Suncor Energy Inc. (NYSE:SU), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 80% are positive. Suncor Energy Inc. had 26 analyst reports since July 21, 2015 according to SRatingsIntel. On Tuesday, January 24 the stock rating was downgraded by Macquarie Research to “Neutral”. The rating was initiated by Wells Fargo on Friday, December 16 with “Outperform”. TD Securities downgraded the shares of SU in report on Thursday, November 16 to “Hold” rating. The stock has “Hold” rating by TD Securities on Wednesday, November 18. The firm has “Buy” rating given on Thursday, June 23 by Citigroup. As per Thursday, December 1, the company rating was upgraded by Desjardins Securities. On Thursday, October 27 the stock rating was upgraded by Macquarie Research to “Outperform”. The company was initiated on Tuesday, March 22 by JP Morgan. The rating was maintained by Citigroup on Wednesday, September 16 with “Neutral”. The rating was initiated by Bank of America on Friday, August 19 with “Buy”. See Suncor Energy Inc. (NYSE:SU) latest ratings:

11/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $44.0 Maintain
21/11/2017 Broker: Edward Jones Old Rating: Hold New Rating: Buy Upgrade
16/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $42.0
16/11/2017 Broker: TD Securities Old Rating: Buy New Rating: Hold Downgrade
13/10/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $48 New Target: $52 Maintain

Since August 3, 2017, it had 0 insider buys, and 11 sales for $1.60 million activity. Turk Joseph E Jr had sold 1,000 shares worth $27,560. Swan Winifred L sold $102,235 worth of stock. On Wednesday, September 20 the insider TOWSE MATTHEW W sold $117,261.

NxStage Medical, Inc., a medical technology company, develops, makes, and markets services and products for patients suffering from chronic or acute kidney failure. The company has market cap of $1.67 billion. The Company’s primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. It currently has negative earnings. The firm operates through three divisions: System One, In-Center, and Services.

Among 9 analysts covering NxStage Medical (NASDAQ:NXTM), 2 have Buy rating, 1 Sell and 6 Hold. Therefore 22% are positive. NxStage Medical has $32 highest and $14 lowest target. $26.44’s average target is 4.80% above currents $25.23 stock price. NxStage Medical had 18 analyst reports since November 4, 2015 according to SRatingsIntel. The rating was downgraded by Craig Hallum on Monday, August 7 to “Hold”. Canaccord Genuity maintained Nxstage Medical, Inc. (NASDAQ:NXTM) on Tuesday, August 2 with “Buy” rating. The rating was reinitiated by Piper Jaffray with “Overweight” on Thursday, March 31. The rating was downgraded by BTIG Research to “Neutral” on Friday, August 11. The stock has “Market Perform” rating by Leerink Swann on Tuesday, August 22. The stock of Nxstage Medical, Inc. (NASDAQ:NXTM) has “Hold” rating given on Monday, August 7 by Canaccord Genuity. The firm earned “Hold” rating on Tuesday, August 8 by Jefferies. Jefferies maintained the shares of NXTM in report on Tuesday, October 10 with “Hold” rating. The firm has “Buy” rating given on Tuesday, June 6 by BTIG Research. On Monday, September 11 the stock rating was maintained by Canaccord Genuity with “Hold”.

The stock increased 1.86% or $0.46 during the last trading session, reaching $25.23. About 338,166 shares traded. Nxstage Medical, Inc. (NASDAQ:NXTM) has risen 21.18% since January 19, 2017 and is uptrending. It has outperformed by 4.48% the S&P500.

Investors sentiment decreased to 0.91 in Q3 2017. Its down 0.23, from 1.14 in 2017Q2. It dropped, as 50 investors sold Nxstage Medical, Inc. shares while 41 reduced holdings. 51 funds opened positions while 32 raised stakes. 51.56 million shares or 12.24% less from 58.75 million shares in 2017Q2 were reported. Rathbone Brothers Public Ltd, a United Kingdom-based fund reported 10,800 shares. American Grp reported 0% in Nxstage Medical, Inc. (NASDAQ:NXTM). Aqr Mngmt Ltd holds 0% in Nxstage Medical, Inc. (NASDAQ:NXTM) or 62,849 shares. Portfolio Solutions holds 245 shares. Adage Capital Ptnrs Gru Limited Liability Co reported 0.01% in Nxstage Medical, Inc. (NASDAQ:NXTM). Sterling Capital Mngmt Ltd Liability Corp has invested 0.02% in Nxstage Medical, Inc. (NASDAQ:NXTM). Yakira Cap Mngmt holds 0.25% in Nxstage Medical, Inc. (NASDAQ:NXTM) or 26,721 shares. Blair William And Il invested in 0.04% or 192,933 shares. Water Island Capital Ltd Limited Liability Company, New York-based fund reported 853,218 shares. California Pub Employees Retirement System invested in 0% or 103,761 shares. Federated Invsts Pa reported 0% stake. Legal And General Group Public Ltd Limited Liability Company accumulated 32,192 shares or 0% of the stock. Pennant Lc stated it has 1.62M shares. 138,368 are owned by Jefferies Grp Ltd Co. Jpmorgan Chase And accumulated 0.01% or 1.87M shares.